Effect of aerosol inhalation of budesonide on respiratory symptoms and inflammatory factors in patients with asthma: a meta-analysis

J Asthma. 2024 Nov;61(11):1581-1589. doi: 10.1080/02770903.2024.2368201. Epub 2024 Jul 5.

Abstract

Objective: To review the efficacy, symptoms, inflammatory factors and pulmonary function of different doses of budesonide aerosol inhalation in the treatment of patients with asthma.

Methods: The Chinese and English literature databases were searched with "Effects of different doses of budesonide aerosol inhalation on the efficacy, lung function, inflammation, symptoms and adverse reactions in patients with asthma" as the search direction, and a Meta-analysis was performed.

Results: Compared with the low dose group, the efficacy, PEF and FEV1 were significantly increased and the clinical symptom score, TNF-α and IL-4 were significantly decreased in the high dose group (p < 0.05). There was no significant difference in IFN-γ level and the incidence of adverse reactions between the two groups (p > 0.05).

Conclusion: High-dose budesonide aerosol inhalation therapy can improve the efficacy and lung function of patients, reduce inflammation and clinical symptoms, and does not increase the risk of adverse reactions, which is worthy of clinical promotion.

Keywords: Asthma; Budesonide atomization inhalation; inflammatory factors; meta-analysis; pulmonary function; symptoms.

Publication types

  • Meta-Analysis

MeSH terms

  • Administration, Inhalation
  • Aerosols / administration & dosage
  • Asthma* / drug therapy
  • Bronchodilator Agents* / administration & dosage
  • Bronchodilator Agents* / adverse effects
  • Bronchodilator Agents* / therapeutic use
  • Budesonide* / administration & dosage
  • Budesonide* / adverse effects
  • Humans
  • Inflammation / drug therapy
  • Interleukin-4
  • Respiratory Function Tests
  • Tumor Necrosis Factor-alpha

Substances

  • Budesonide
  • Bronchodilator Agents
  • Aerosols
  • Tumor Necrosis Factor-alpha
  • Interleukin-4